Overview Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy Status: Completed Trial end date: 2021-04-01 Target enrollment: Participant gender: Summary Safety Assessment of APL-2 in Patients with Geographic Atrophy Phase: Phase 1 Details Lead Sponsor: Apellis Pharmaceuticals, Inc.